Ensign Peak Advisors
CCCC icon

Ensign Peak Advisors’s C4 Therapeutics CCCC Stock Holding History

Ensign Peak Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,230
Closed -$63K – 1857
2022
Q3 		$63K Buy
7,230
+4,670
+182% +$48.5K ﹤0.01% 2173
2022
Q2 		$19K Sell
2,560
-25,793
-91% -$227K ﹤0.01% 2128
2022
Q1 		$688K Hold
28,353
– – ﹤0.01% 1412
2021
Q4 		$913K Buy
28,353
+2,560
+10% +$101K ﹤0.01% 1347
2021
Q3 		$1.15M Sell
25,793
-14,207
-36% -$608K ﹤0.01% 1380
2021
Q2 		$1.51M Hold
40,000
– – ﹤0.01% 1266
2021
Q1 		$1.48M Hold
40,000
– – ﹤0.01% 1256
2020
Q4 		$1.32M Buy
+40,000
New +$1.16M ﹤0.01% 1275

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's CCCC Position: Q4 2022 in Review

Ensign Peak Advisors sold out of C4 Therapeutics (CCCC) in Q4 2022, closing a stake of 7,230 shares — an estimated $63K sold.

Ensign Peak Advisors first reported a position in CCCC in Q4 2020 and held it in 8 quarters. The position peaked at $1.51M in Q2 2021. 117 funds tracked by Wall St. Rank hold CCCC as of Q4 2022.

  • Ensign Peak Advisors reported no remaining C4 Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 7,230 C4 Therapeutics shares in Q4 2022, an estimated $63K.
  • Ensign Peak Advisors first reported a position in C4 Therapeutics in Q4 2020 and held it in 8 quarters.
  • Ensign Peak Advisors's C4 Therapeutics position peaked at $1.51M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.